All relevant data are within the paper.

Introduction {#sec001}
============

Erythropoietin (EPO) is a hematopoietic cytokine that regulates the rate of red blood cell production \[[@pone.0124676.ref001], [@pone.0124676.ref002]\]. It binds to EPO receptors (EPORs) on the surface of erythroid progenitors, and then causes a preformed EPOR homodimer to undergo a conformational change which activates signal transduction pathways. The signal transduction events promote the survival, proliferation, and differentiation of erythroid progenitors, causing an increase in the number of circulating mature red blood cells. In humans and mice, EPO is a heavily glycosylated protein produced by adult kidneys, and is targeted to the bone marrow via blood circulation. The carbohydrate chain plays a part in the prevention of EPO being cleared from blood circulation, and therefore is vital for *in vivo* biological activity \[[@pone.0124676.ref003]--[@pone.0124676.ref010]\].

Erythropoiesis is one of the common functions widely conserved among vertebrates. Thus far, EPO sequences have been elucidated in at least 13 mammalian species \[[@pone.0124676.ref011]--[@pone.0124676.ref020]\], one amphibian (African clawed frog, *Xenopus laevis*) \[[@pone.0124676.ref021]\], and 3 teleost fish (pufferfish, *Takifugu rubripes*; zebrafish, *Danio rerio*; and goldfish, *Carassius auratus L*.) \[[@pone.0124676.ref022]--[@pone.0124676.ref025]\]. Interspecific comparison of the functional region can provide an insight into the universal structure-function relationships among EPO proteins. The functional region responsible for the receptor binding and biological activity of human EPO (huEPO) is described by several studies \[[@pone.0124676.ref026]--[@pone.0124676.ref030]\]. However, in other species, especially non-mammals, the functional region of EPO remains unexplored.

Previously, we described the cloning of *X*. *laevis* EPO (*xl*EPO) and its *in vitro* activity by a colony formation assay \[[@pone.0124676.ref021], [@pone.0124676.ref031]\]. Intriguingly, we found that *xl*EPO stimulates the proliferation of the cells that express human EPOR (huEPOR), even though the amino acid sequence of *xl*EPO is only 38% identical to that of huEPO \[[@pone.0124676.ref021]\]. This led us to expect that the functional region of EPO, which is responsible for *in vitro* activity, is conserved between *X*. *laevis* and humans. In light of this assumption, there are several findings that helped us to generate a working hypothesis. First, *xl*EPO has no *N*-glycosylation site \[[@pone.0124676.ref021]\], whereas huEPO has 3 *N*-glycosylation sites (at Asn24, Asn38, and Asn83) that are distal to the receptor-binding site \[[@pone.0124676.ref032]\]. Remarkably, these 3 *N*-glycosylation sites \[[@pone.0124676.ref013]\] and their biological cross-reactivity \[[@pone.0124676.ref033]--[@pone.0124676.ref036]\] are conserved in a number of mammalian EPOs. In addition, it has been observed that in huEPO glycosylation analogs with additional *N*-linked carbohydrates, the positions of the carbohydrate chains have an impact on whether the analog retains its *in vitro* biological activity \[[@pone.0124676.ref032], [@pone.0124676.ref037]\]. In light of these facts, we hypothesized that the activity of *xl*EPO should be retained, even if we introduce *N*-glycosylation sites to regions homologous to the 3 *N*-glycosylation sites of huEPO.

In this study, we tested this hypothesis by examining the activity of *xl*EPO muteins containing artificial *N*-glycosylation sites at positions homologous to those in huEPO (i.e., Asn24, Asn38, and Asn83). Those *xl*EPO muteins retained *in vitro* activity, demonstrating that the fundamental conformations of EPO-EPOR binding are conserved among humans and *X*. *laevis*; despite the low similarity in the primary sequences.

Notation of gene and protein symbols {#sec002}
------------------------------------

The gene and protein symbols of *Xenopus* are suggested in Xenbase (Gene Nomenclature Guidelines; <http://xenbase.org/gene/static/geneNomenclature.jsp>). However, for reporting the comparative analysis of EPO in this study, we named the *X*. *laevis* erythropoietin protein "*xl*EPO" instead of xlepo.

Materials and Methods {#sec003}
=====================

Construction of *N-*glycosylated *xl*EPO muteins {#sec004}
------------------------------------------------

*N*-glycosylated *xl*EPO muteins were constructed by introducing *N*-glycosylation consensus sequences (Asn-Xxx-Ser/Thr, where Xxx is any amino acid except Pro) into a region homologous to that of huEPO. Each *N*-glycosylation site results from the mutation of Thr24 Met26 to Asn24 Thr26, Asp38 Met40 to Asn38 Thr40, and Asp83 to Asn83 ([Fig 1A](#pone.0124676.g001){ref-type="fig"} and [Table 1](#pone.0124676.t001){ref-type="table"}). *N*-glycosylated *xl*EPO cDNAs were produced by *in vitro* multiple site-directed mutagenesis of the *xl*EPO cDNA, as described below.

![Design of *N*-glycosylated *xl*EPO muteins.\
(**A**) Schematic drawings of *Xenopus laevis* erythropoietin (*xl*EPO) muteins. *N*- and *O*-glycosylation sites are indicated by closed and opened rhombuses, respectively. The terms to the left of the bars represent the names of the muteins. "X" in *xl*EPO-XXX indicates *N*-glycosylation positions (1, Asn24; 2, Asn38; 3, Asn83). (**B**) Amino acid sequences around the introduced *N*-glycosylation sites in the *xl*EPO muteins. The parallel sequences of wild-type *xl*EPO, human EPO, and mouse EPO are also shown. Consensus sequences for *N*-glycosylation (Asn-Xxx-Ser/Thr) are underlined, with the amino acid substitutions in bold.](pone.0124676.g001){#pone.0124676.g001}

10.1371/journal.pone.0124676.t001

###### Primers used for multiple site-directed mutagenesis.

![](pone.0124676.t001){#pone.0124676.t001g}

  Primer              Oligonucleotide sequence (5′--3′)
  ------------------- -------------------------------------------------------------------------------------------------
  Thr24Asn/Met26Thr   AGAGAATTGGAA[A**AC**]{.ul}GCC[A**C**G]{.ul}GACTCCTGCAAC[^*a*^](#t001fn001){ref-type="table-fn"}
  Asp38Asn/Met40Thr   CAATTTCCTGAG[**A**AT]{.ul}ATC[A**C**G]{.ul}GTCCCTGAAAC[^*a*^](#t001fn001){ref-type="table-fn"}
  Asp83Asn            ATTTCATCTCC[**A**AT]{.ul}GCCAGCCTC[^*a*^](#t001fn001){ref-type="table-fn"}
  tailed 5′-anchor    *ACTTGCGGATCCATGGC*GCTAGCCACC[ATG]{.ul}GGTGT[^*b*^](#t001fn002){ref-type="table-fn"}
  tailed 3′-anchor    GCTAGTCTACCAACG[TGA]{.ul} *CGGTCGTTAACAGCTCT* [^*b*^](#t001fn002){ref-type="table-fn"}
  PCR 5′-anchor Fw    ACTTGCGGATCCATGGC
  PCR 3′-anchor Re    AGAGCTGTTAACGACCG

^*a*^The codons for mutated amino acids are underlined, with the point mutations in bold.

^*b*^The start and stop codons are underlined and the unique nucleotide tail for subsequent mutant strand-specific PCR is in italics.

Fw, forward; Re, reverse.

Multiple site-directed mutagenesis and preparation of expression plasmids {#sec005}
-------------------------------------------------------------------------

Mutagenesis was performed as described by Seyfang and Jin \[[@pone.0124676.ref038]\], with some modifications. Double-stranded plasmid DNA containing the *xl*EPO gene \[[@pone.0124676.ref021]\] was used as a template. Mutagenic primers and tailed 5′- and 3′-anchor primers ([Table 1](#pone.0124676.t001){ref-type="table"}) were phosphorylated before the annealing reaction. Two terminal-tailed primers with a unique 17-nucleotide tail ([Table 1](#pone.0124676.t001){ref-type="table"}) were simultaneously annealed to the template DNA along with the set of mutagenic primers. Mutant strands were synthesized by primer extension and ligation in a single incubation step using T4 DNA polymerase and ligase. Full-length mutant strands were subsequently amplified by high-fidelity PCR with *Pfu* polymerase, which uses the unique mutant strand-specific tails introduced by the 2 terminal anchor primers. The specificity and band size of the amplified mutagenesis products were confirmed by 1.5% agarose gel electrophoresis. Following gel extraction and purification (QIAEX II Gel Extraction Kit; QIAGEN K.K., Tokyo, Japan) of the 584-bp band, the extracted DNA was cloned into a pGEM-T Easy vector (Promega K.K., Tokyo, Japan) and sequenced using an ABI3100 Genetic Analyzer (Applied Biosystems) and dye-terminator chemistry (BigDye Terminator; Applied Biosystems). Plasmids containing the desired mutations were digested with *Nhe*I and *Eco*RI. The DNA fragments were then cloned into the multiple cloning site (MCS) of the pIRES2-EGFP expression vector (BD Biosciences Clontech) containing the human cytomegalovirus immediate early promoter and an SV40 early polyadenylation signal sequence. pIRES2-EGFP contains the internal ribosome entry site (IRES) of the encephalomyocarditis virus between the MCS and the EGFP coding region; this enables both the *xl*EPO gene and the EGFP gene to be translated from a single bicistronic mRNA.

All constructs were transformed into *E*. *coli* DH5*α*. Several colonies were subsequently grown in Luria-Bertani broth containing 50 μg/mL of kanamycin. The plasmids were isolated using the alkaline-SDS lysis method.

Expression of *xl*EPO muteins in COS-1 cells {#sec006}
--------------------------------------------

Monkey kidney fibroblast COS-1 cells (Cell Bank, RIKEN BioResource Center, Ibaraki, Japan) were transfected with vectors that incorporated the full coding sequence of the *xl*EPO genes. COS-1 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin in a humidified atmosphere of 5% CO~2~ at 37°C. Cells (8 × 10^4^ cells/well) were seeded in 24-well cell culture plates (Corning Incorporated, NY, USA). When the cultures reached 90% confluence, cells were transfected with a mixture of 0.8 μg plasmid cDNA and 1.5 μL Lipofectamine LTX (Life Technologies Corporation) per well in 100 μL Opti-MEM (Life Technologies Corporation) for 4 h at 37°C. After transfection, cells were incubated in antibiotic-free DMEM containing 10% FBS for 24 h. Cells were then incubated in serum-free, antibiotic-containing DMEM. After an additional 48 h, EGFP fluorescence was measured (excitation 485 nm, emission 528 nm) and conditioned media were collected. The collected media were arbitrarily concentrated using centrifugal filter devices (Amicon Ultra-4, 5000 NMWL; Millipore Corporation, Billerica, MA, USA) and stored at---80°C. Expression of the *xl*EPO muteins was confirmed by SDS-PAGE followed by Western blotting.

Gel electrophoresis and Western blot analyses {#sec007}
---------------------------------------------

Samples were reduced by boiling for 5--10 min in sample buffer (50 mM Tris-HCl (pH 6.8), 20 mM dithiothreitol, 1% w/v SDS, 10% v/v glycerol, 2 mM EDTA, and 0.005% bromophenol blue) and subjected to SDS-PAGE with a separating gel containing 14% acrylamide. Protein markers (Biotinylated SDS-PAGE Standard Low Range; Bio-Rad Laboratories Inc.) were used for electrophoretic estimation of molecular weights. After electrophoresis, the proteins were transferred to a polyvinylidene difluoride membrane (Millipore). Protein transfer was carried out for 30 min with a constant current of 150 mA in a semi-dry electroblotter (Continental Lab Products Inc., San Diego, CA, USA) using anolyte (0.3 M Tris (pH 10.4) and 20% v/v methanol), transfer membrane (25 mM Tris (pH 10.4) and 20% v/v methanol), and catholyte solutions (25 mM Tris (pH 10.4) and 40 mM 6-amino-*n*-caproic acid, 20% v/v methanol). The blots were washed once with TBS (20 mM Tris-HCl (pH 7.5) and 500 mM NaCl) and then twice with TBS containing 0.1% (v/v) Tween 20 (TTBS). After blocking with 0.4% Block Ace (Snow Brand Milk Products Co., Ltd., Hokkaido, Japan) in TTBS for 45 min, each blot was incubated for 1 h with 2 μg/mL anti-peptide antibody against the *xl*EPO Thr44 to Ser57 sequence (anti-*xl*EPO sequence antibody) \[[@pone.0124676.ref031]\] or anti-GFP antibody (Medical & Biological Laboratories Co., Ltd., Nagoya, Japan) and then washed twice with TTBS. The blots were subsequently incubated for 1 h with biotinylated goat anti-rabbit IgG (1:6000; Bio-Rad), washed twice with TTBS, and treated with alkaline phosphatase-conjugated StrepTactin (1:6000; Bio-Rad) for 1 h. After 2 washes with TTBS followed by 2 more washes with TBS, proteins were detected by chemiluminescence (CDP-Star reagent; GE Healthcare Ltd., Tokyo, Japan). The bands were detected using a Luminescent Image analyzer LAS-3000 (Fuji Photo Film Co., Ltd., Tokyo, Japan). All washes were carried out for 5 min. All antibodies and alkaline phosphatase-conjugated StrepTactin were prepared in TTBS containing 0.4% Block Ace.

Physicochemical analysis of *xl*EPO muteins {#sec008}
-------------------------------------------

Wild-type *xl*EPO and *N*-glycosylated muteins in mixed conditioned media were separated by reverse-phase high-pressure liquid chromatography (RP-HPLC) and cation exchange chromatography (CIEC). In RP-HPLC, the sample was applied at a flow rate of 0.4 mL/min to a YMC-Pack Protein-RP column (4.5 × 150 mm; YMC Co., Ltd., Tokyo, Japan) and separated with a linear gradient of 20%--60% acetonitrile in 0.1% trifluoroacetic acid over 30 min. A total of 10 fractions was collected once every 3 min (1.2 mL). In CIEC, the samples were adjusted to pH 2 with acetic acid, applied to 200 μL of SP Sepharose FF column (GE Healthcare), and eluted with 50 mM citrate/100 mM phosphate buffer (pH 2, 3, 4... 9). Each fraction was subjected to Western blot analysis.

De-*N*-glycosylation of *xl*EPO muteins {#sec009}
---------------------------------------

*N*-linked carbohydrates were removed by incubation with or without 0.8 U peptide *N*-glycosidase F (PNGase F; Roche Diagnostics K.K., Tokyo, Japan) in 20 mM sodium phosphate buffer (pH 8.6) containing 10 mM EDTA at 37°C for 24 h. Carbohydrate removal was assessed by SDS-PAGE and Western blot analysis.

Cell proliferation assay {#sec010}
------------------------

Cell proliferation assays were performed as previously described \[[@pone.0124676.ref021]\]. Two cell lines were used: the interleukin-3-dependent murine cell line FDC/P2, which expresses the exogenous *xl*EPO receptor, *xl*EPOR-FDC/P2 \[[@pone.0124676.ref021]\], and the EPO-dependent human cell line, UT-7/EPO \[[@pone.0124676.ref039]\]. In the MTS assay, absorbance at 450 nm was measured using a microplate reader (POWERSCAN HT; DS Pharma Biomedical Co., Ltd., Osaka, Japan). Dose-response curves were fitted to a 4-parameter logistic model: *y* = (*a---d*) / {1 + (*x* / *c*) *b*} + *d*, where, *a* is *E* ~max~ and *c* is *EC* ~50~ \[[@pone.0124676.ref040]\]. Then, the *E* ~max~ (maximum effect) of the *xl*EPO mutein was determined without normalization by protein amount. The relative *EC* ~50~ (half-maximal effective concentration) of the *xl*EPO mutein was determined via normalization of v/v % of COS-1 supernatant *EC* ~50~ with its relative amount in COS-1 supernatant.

Statistical analysis {#sec011}
--------------------

All experiments were performed at least 3 times with triplicate samples, and similar results were obtained each time. Error bars represent the standard deviations (SD). Either Student's *t*-test or the Tukey--Kramer test was used, when appropriate.

Results {#sec012}
=======

Design and expression of *N*-glycosylated *xl*EPO muteins {#sec013}
---------------------------------------------------------

We introduced *N*-glycosylation consensus sequences into the *xl*EPO at positions homologous to those of huEPO (i.e., Asn24, Asn38, and Asn83) using *in vitro* mutagenesis ([Fig 1A](#pone.0124676.g001){ref-type="fig"}). The mutations were introduced both individually and in combinations. Thus, we constructed 7 different *N*-glycosylated *xl*EPO muteins with consensus sequences introduced at 3 different positions ([Fig 1B](#pone.0124676.g001){ref-type="fig"}). The wild-type *xl*EPO and *N*-glycosylated muteins were expressed in COS-1 cells using the lipofection method. All muteins were secreted from the COS-1 cells. The extent of glycosylation was evaluated by Western blot analysis using the anti-*xl*EPO sequence antibody ([Fig 2A](#pone.0124676.g002){ref-type="fig"}, *top panel*). The molecular weight of wild-type *xl*EPO was 18 kDa, which is equivalent to that of the peptide backbone. Western blots showed progressive increases in the molecular weights of *xl*EPO muteins from 18 to 22, 26, and 30 kDa, depending on the number of *N*-linked carbohydrates added. Treatment with PNGase F, which removes *N*-linked carbohydrates from glycoproteins, shifted the molecular weights of all muteins to 18 kDa, or the molecular weight of the wild type ([Fig 2A](#pone.0124676.g002){ref-type="fig"}, *bottom panel*). Thus, the increase in the size of the muteins in comparison to the wild-type *xl*EPO was attributed to *N*-linked carbohydrate content. Non-glycosylated Asn83 was observed in *xl*EPO-3, *xl*EPO-13, *xl*EPO-23, and *xl*EPO-123, which indicates that carbohydrate additions were efficient at Asn24 and Asn38, but inefficient at Asn83. The glycosylated *xl*EPO molecules showed 2 bands: a main band and a smaller one. These 2 bands were not observed after PNGase F treatment. This result shows that these 2 bands result from heterogeneity in the *N*-linked carbohydrate structure. The unsecreted protein was also examined by Western blot analysis ([Fig 2B](#pone.0124676.g002){ref-type="fig"}). Whole-cell lysates were loaded into each lane, and EGFP was used as a loading control to normalize the signals ([Fig 2B](#pone.0124676.g002){ref-type="fig"}, *bottom panel*). The wild-type *xl*EPO and *N*-glycosylated muteins left in the cell were detected ([Fig 2B](#pone.0124676.g002){ref-type="fig"}, *top panel*). To estimate the amount of *xl*EPO muteins in the COS-1 supernatant, we performed a densitometry analysis of Western blots. In Western blot analysis, the recognition of hyperglycosylated huEPO analogs by an anti-huEPO sequence antibody was reported to be weak compared with huEPO recognition, and was improved by the partial elimination of carbohydrate chains \[[@pone.0124676.ref041]\]. Therefore, we used Western blots of deglycosylated samples ([Fig 2A](#pone.0124676.g002){ref-type="fig"}, *bottom panel*) for densitometry analysis, because the added *N*-linked carbohydrates may prevent the anti-*xl*EPO sequence antibody from binding to the *xl*EPO muteins. The band intensity of wild-type *xl*EPO was defined as 1. The analysis revealed that the relative amount of *xl*EPO muteins in the COS-1 supernatant decreased depending on the number of *N*-linked carbohydrates added ([Fig 2C](#pone.0124676.g002){ref-type="fig"}). The detected amounts of the muteins, *xl*EPO-1, *xl*EPO-2, and *xl*EPO-3, containing 1 *N*-glycosylation site were approximately half that of the wild type. Moreover, the amounts of the muteins, *xl*EPO-12, *xl*EPO-23, and *xl*EPO-123, containing 2 or 3 *N*-glycosylation sites were only about one-quarter that of the wild type. Because the IRES-containing expression vector enables *xl*EPO and EGFP to be co-expressed from a single bicistronic mRNA, EGFP fluorescence intensity reflects *xl*EPO expression at the mRNA level. Therefore, the relative secretion efficiency of *xl*EPO muteins was obtained by dividing the relative amount (i.e. relative secretion level) by the relative expression level ([Fig 2C](#pone.0124676.g002){ref-type="fig"}). As a result, the secretion efficiencies of *xl*EPO muteins were revealed to decrease as the number of *N*-linked carbohydrates added increased, suggesting that glycosylation may have an adverse effect on *xl*EPO secretion.

![Expression, secretion, and physicochemical properties of *N*-glycosylated *xl*EPO muteins.\
(**A**) Western blot analysis of *xl*EPO muteins secreted from COS-1 cells. Conditioned media were concentrated 10-fold (*top panel*), and subjected to PNGase F treatment (*bottom panel*). Wild-type *xl*EPO and *N*-glycosylated muteins were separated by SDS-PAGE (reducing conditions) and visualized by Western blot analysis. Equal volumes of samples were loaded into each lane. (**B**) Western blot analysis of *xl*EPO muteins remaining in COS-1 cells. Whole-cell lysates were loaded into each lane. *xl*EPO (*top panel*) and EGFP (*bottom panel*) were visualized by Western blot analysis. Co-expressed nonsecretory EGFP was used as a loading control. (A, B) Standard proteins are shown at the far left, and the letters above each lane represent the names of the muteins shown in [Fig 1](#pone.0124676.g001){ref-type="fig"}. (**C**) Effects of *N*-glycosylation on the secretion of *xl*EPO muteins. The relative amounts of *xl*EPO muteins in the culture media of COS-1 cells were measured by densitometry analysis of Western blots (*filled bars*). The relative expression levels were calculated based on the fluorescence intensity of co-expressed EGFP (*open bars*). The relative efficiency of secretion was obtained by the division of relative amount by relative expression level (*open circles*). Values were normalized to that of the wild type, which was set at 1. \**p* \< 0.05 and \*\**p* \< 0.01 compared to the wild type. (**D**) Physicochemical properties of *xl*EPO muteins. Cation-exchange chromatography (CIEC, *top panel*) and the reverse-phase high-pressure liquid chromatography (RP-HPLC, *bottom panel*) of wild-type *xl*EPO and *N*-glycosylated muteins were performed as described in the *Materials and methods* section. The collected fractions were subjected to Western blot analysis. '*N*-CHO' indicates the number of *N*-linked carbohydrates. Abbreviations are: EB, elution buffer; Fr., fraction.](pone.0124676.g002){#pone.0124676.g002}

Physicochemical properties of *xl*EPO muteins {#sec014}
---------------------------------------------

The physicochemical properties of proteins, such as the electrical charge and hydrophilicity, affect their ligand--receptor binding affinity and/or protein stability in blood \[[@pone.0124676.ref042], [@pone.0124676.ref043]\]. To predict the isoelectric point (p*I*) of the *xl*EPO muteins, CIEC was performed ([Fig 2D](#pone.0124676.g002){ref-type="fig"}, *top panel*). Wild-type *xl*EPO was eluted at pH 8--9, and the *xl*EPO muteins containing 1 or 2 *N*-linked carbohydrates were eluted mainly at pH 7 or 8, respectively. Next, RP-HLPC was performed, in order to examine the hydrophilicity of the *xl*EPO muteins ([Fig 2D](#pone.0124676.g002){ref-type="fig"}, *bottom panel*). Wild-type *xl*EPO was eluted in fraction (Fr.) 9 at 52%--58% acetonitrile. Meanwhile, *xl*EPO muteins with 1 or 2 *N*-linked carbohydrates were eluted in earlier fractions (Fr. 8, 46%--52% acetonitrile or Fr. 7, 40%--46% acetonitrile, respectively). These results indicate that the *xl*EPO muteins are more acidic and hydrophilic than the wild type, owing to the negative charge of *N*-linked carbohydrates.

*In vitro* activity of *xl*EPO muteins {#sec015}
--------------------------------------

The effects of the added *N*-linked carbohydrates on the *in vitro* activity of *xl*EPO muteins were tested in cell proliferation assays using exogenous *xl*EPOR-expressing *xl*EPOR-FDC/P2 cells ([Fig 3A](#pone.0124676.g003){ref-type="fig"}), and huEPOR-expressing UT-7/EPO cells ([Fig 3B](#pone.0124676.g003){ref-type="fig"}). As expected, all *xl*EPO muteins stimulated the proliferation of both cell lines in a dose-dependent manner. Usually, dose-response curves as descriptors of ligand activity are characterized by differences in potency (described as *EC* ~50~) and efficacy (described as *E* ~max~). Then, the relative potency and the relative efficacy of the *xl*EPO muteins on the proliferation of *xl*EPOR-FDC/P2 and UT-7/EPO cells were evaluated ([Table 2](#pone.0124676.t002){ref-type="table"} and [Fig 4](#pone.0124676.g004){ref-type="fig"}). As the number of *N*-linked carbohydrates increased, the relative potency of *xl*EPO muteins, which was obtained from the relative *EC* ~50~, tended to decrease in both cell lines ([Fig 4A and 4B](#pone.0124676.g004){ref-type="fig"}). On the other hand, the effect of *N*-linked carbohydrates on the relative efficacy of *xl*EPO muteins, which was obtained from *E* ~max~, differed between the cell lines ([Fig 4C and 4D](#pone.0124676.g004){ref-type="fig"}). The efficacy on the proliferation of *xl*EPOR-FDC/P2 cells tended to decrease, as the number of *N*-linked carbohydrates increased ([Fig 4C](#pone.0124676.g004){ref-type="fig"}). More specifically, the efficacy of *xl*EPO-12 and *xl*EPO-23 was significantly lower than that of wild-type *xl*EPO, and *xl*EPO-1 and *xl*EPO-13 also showed a slightly lower efficacy compared to the wild type ([Table 2](#pone.0124676.t002){ref-type="table"}). In contrast, the efficacy of the *xl*EPO muteins on the proliferation of UT-7/EPO cells was not significantly affected by the addition of *N*-linked carbohydrates ([Fig 4D](#pone.0124676.g004){ref-type="fig"} and [Table 2](#pone.0124676.t002){ref-type="table"}). To confirm that the decrease in the activity of *xl*EPO muteins (*EC* ~50~ and *E* ~max~) is attributed to the addition of *N*-linked carbohydrates, PNGase F-treated COS-1 supernatant was assayed by the proliferation of *xl*EPOR-FDC/P2 cells ([Fig 3C](#pone.0124676.g003){ref-type="fig"}). Removal of *N*-linked carbohydrates with PNGase F increased the *in vitro* activity of the *xl*EPO muteins ([Fig 3C](#pone.0124676.g003){ref-type="fig"}, *middle and right panels*), except *xl*EPO-3 ([Fig 3C](#pone.0124676.g003){ref-type="fig"}, *left panel*), when COS-1 supernatants were added at a final concentration of 6%. This indicates that the added *N*-linked carbohydrates decreased the *in vitro* activity of *xl*EPO.

![Effects of wild-type *xl*EPO and the glycosylated muteins on the proliferation of *X*. *laevis* and human EPOR-expressing cells.\
(**A, B**) The proliferative responses of *xl*EPOR-FDC/P2 cells (A) and UT-7/EPO cells (B) to the wild-type *xl*EPO and the *N*-glycosylated muteins were assessed using the MTS assay. Incubations were performed in triplicate, and the results are presented as the mean (± SD) from 1 of 4 independent experiments. (**C**) The proliferative responses of *xl*EPOR-FDC/P2 cells to wild-type *xl*EPO and the *N*-glycosylated muteins treated with (*dashed line*) and without (*solid line*) PNGase F were also assessed. The PNGase F-treated samples are the same fractions displayed in [Fig 2A](#pone.0124676.g002){ref-type="fig"}, *bottom panel*. Incubations were performed in triplicate, and the results are presented as the mean (± SD) from 1 of 3 independent experiments. \*\**p* \< 0.01 for the comparison. Symbols are: *multiple marks*, wild-type *xl*EPO; *open squares*, *xl*EPO-1; *open triangles*, *xl*EPO-2; *open circles*, *xl*EPO-3; *closed squares*, *xl*EPO-12; *closed triangles*, *xl*EPO-13; *closed circles*, *xl*EPO-23; *closed rhombuses*, *xl*EPO-123; *plus sign*, Mock (control culture supernatant without *xl*EPO).](pone.0124676.g003){#pone.0124676.g003}

![Relationship between carbohydrate content and biological activity.\
The COS-1 supernatants containing the wild-type *xl*EPO and the *N*-glycosylated muteins were assayed by proliferation of *xl*EPOR-FDC/P2 cells (A, C) and UT-7/EPO cells (B, D). *EC* ~50~-derived relative potency (A, B) and *E* ~max~-derived relative efficacy (C, D) are shown as a percentage relative to the wild-type *xl*EPO ([Table 2](#pone.0124676.t002){ref-type="table"}) and are plotted against the number of added *N*-glycosylation sites. Each point represents different *xl*EPO muteins.](pone.0124676.g004){#pone.0124676.g004}
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###### Relative *in vitr*o activities of *xl*EPO muteins.

![](pone.0124676.t002){#pone.0124676.t002g}

                Relative *EC* ~50~ [^*a*^](#t002fn001){ref-type="table-fn"} (relative potency, %)[^*b*^](#t002fn002){ref-type="table-fn"}   Relative efficacy~,~ %[^*c*^](#t002fn003){ref-type="table-fn"}                                                    
  ------------- --------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------ ----------
  *xl*EPO-1     3.84 ± 0.54 (26)                                                                                                            1.34 ± 0.27 (74)                                                 84 ± 15                                          106 ± 9
  *xl*EPO-2     1.35 ± 0.79 (74)                                                                                                            5.17 ± 4.07 (19)                                                 101 ± 5                                          108 ± 27
  *xl*EPO-3     3.54 ± 1.50 (28)                                                                                                            2.37 ± 0.48 (42)                                                 94 ± 6                                           100 ± 14
  *xl*EPO-12    8.65 ± 1.58[\*\*](#t002fn005){ref-type="table-fn"} (12)                                                                     3.24 ± 2.88 (31)                                                 54 ± 16[\*\*](#t002fn005){ref-type="table-fn"}   96 ± 8
  *xl*EPO-13    4.47 ± 2.97 (22)                                                                                                            1.05 ± 0.43 (95)                                                 89 ± 8                                           97 ± 20
  *xl*EPO-23    3.25 ± 1.41 (31)                                                                                                            6.64 (15)                                                        74 ± 14[\*](#t002fn004){ref-type="table-fn"}     91
  *xl*EPO-123   N.D.                                                                                                                        187 (0.54)                                                       N.D.                                             103

^*a*^The relative half-maximal effective concentrations (*EC* ~50~) of the *xl*EPO muteins. *EC* ~50~ of wild-type *xl*EPO was defined as 1. Values are presented as mean ± SD of 2--4 independent experiments.

^*b*^The relative potencies are expressed as the value of the wild type equal to 100%.

^*c*^The relative efficacy of the *xl*EPO muteins. Values were obtained from maximum effects (*E* ~max~) as the value of wild-type *xl*EPO equal to 100%. Values are presented as mean ± SD of 2--4 independent experiments.

\**p* \< 0.05 and

\*\**p* \< 0.01 for the muteins compared with the wild type.

N.D., not determined.

Discussion {#sec016}
==========

In this study, we produced 7 different *N*-glycosylated *xl*EPO muteins and compared their biochemical properties of (i) secretion, (ii) physicochemical properties, and (iii) *in vitro* activity to those of the wild type.

The relative secretion efficiencies of the *xl*EPO muteins decreased depending on the number of *N*-linked carbohydrates added ([Fig 2C](#pone.0124676.g002){ref-type="fig"}). When the carbohydrate is added to the partially folded protein during translation \[[@pone.0124676.ref044]\], it has been hypothesized that the rates of synthesis or folding have a competitive relationship with the addition of the carbohydrate \[[@pone.0124676.ref045]\]. In light of this, the addition of carbohydrates was thought to reduce the secretion of *xl*EPO muteins at translation and/or during the secretion process.

Wild-type *xl*EPO was absorbed to the cation exchanger at pH 7 ([Fig 2D](#pone.0124676.g002){ref-type="fig"}). The pH of *X*. *laevis* plasma is approximately 7.4, the same as that of human plasma \[[@pone.0124676.ref046]\]. This indicates that wild-type *xl*EPO bears a positive electric charge in blood, whereas huEPO (p*I*, 4.4--5.1) bears a negative charge \[[@pone.0124676.ref047]\]. In case of huEPO, sialic acid of carbohydrates, which is negatively charged at physiological pH, is thought to decrease EPOR binding via charge repulsion. Accordingly, wild-type *xl*EPO is thought to easily access EPORs on cells compared to huEPO.

All *N*-glycosylated *xl*EPO muteins retained *in vitro* activity against the cell proliferation of both *xl*EPOR-FDC/P2 and UT-7/EPO ([Fig 3A and 3B](#pone.0124676.g003){ref-type="fig"}). The *EC* ~50~ and *E* ~max~ of a ligand represent the ability of the ligand to bind to its receptor (i.e., potency which reflects receptor-binding affinity) and its ability to cause an effect after binding to the receptor (i.e., efficacy which is intrinsic acticity), respectively. In the present study, we showed the relative *EC* ~50~ because we were able to roughly quantify the relative amounts of wild-type *xl*EPO and *N*-glycosylated muteins in conditioned media. As a result, we found that the addition of *N*-linked carbohydrates decreased the *EC* ~50~-derived relative potency of *xl*EPO muteins ([Fig 4A and 4B](#pone.0124676.g004){ref-type="fig"}). It has been reported that *N*-linked carbohydrates reduce the affinity of huEPO for its receptor, as well as the *in vitr*o activity of huEPO \[[@pone.0124676.ref005]\]. This can be explained as follows: the negatively charged sialic acid and carbohydrate individually decrease the association rate constant of huEPO with huEPOR *via* their negative effect on intrinsic electrostatic enhancement \[[@pone.0124676.ref042]\]. It is also known that darbepoetin alfa, a hyperglycosylated huEPO analog with 2 extra *N*-linked carbohydrates, shows lower receptor-binding activity than huEPO \[[@pone.0124676.ref048]\]. Here, we confirmed that the *N*-glycosylated *xl*EPO muteins are more negatively charged than the wild type ([Fig 2D](#pone.0124676.g002){ref-type="fig"}). Taken together, it is thought that one of the reasons for reduced potencies of muteins is their lower receptor-binding affinities than that of wild type due to negative charge of carbohydrates.

Type of ligand effect on a receptor can be classified according to its behavior. Full agonists elicit the same level of full effect (i.e. *E* ~max~, efficacy) as the natural ligand of the receptor, while partial agonists also cause an effect, but they cannot reach the same level of the natural ligand. The efficacy of the *xl*EPO muteins on *xl*EPOR-FDC/P2 cell proliferation was less than that of wild-type *xl*EPO ([Fig 4C](#pone.0124676.g004){ref-type="fig"}). In particularly, the efficacy of the *xl*EPO muteins containing *N*-linked carbohydrates on Asn24 was remarkably lower than that of wild-type *xl*EPO ([Table 2](#pone.0124676.t002){ref-type="table"}). These data indicate that the muteins act as partial agonists against *xl*EPOR, and also suggest that the carbohydrate structure located at Asn24 interferes with *xl*EPOR binding. In contrast, the efficacy of *xl*EPO on the proliferation of UT-7/EPO cells was not changed by the addition of *N*-linked carbohydrates ([Fig 4D](#pone.0124676.g004){ref-type="fig"}). The *E* ~max~ of wild-type *xl*EPO and the *N*-glycosylated muteins was approximately the same as that of huEPO. These data indicate that the muteins act as near-full agonists against huEPOR, and also suggest that the *N*-linked carbohydrates at the Asn24, Asn38, and Asn83 sites of the *xl*EPO muteins do not interfere with huEPOR binding. Analysis of the effect of point mutations on bioactivity \[[@pone.0124676.ref026]--[@pone.0124676.ref029]\] and the crystal structure of huEPO, complexed with the extracellular ligand-binding domains of huEPOR \[[@pone.0124676.ref030]\], have identified amino acid residues important for receptor binding and biological activity. Twelve of the 18 amino acid residues that reduce the *in vitro* bioactivity of huEPO following point mutations, and interact with huEPOR residues, are conserved in *xl*EPO (6 of 10 in site 1, 6 of 8 in site 2), despite an only 38% overall sequence identity between *xl*EPO and huEPO ([Table 3](#pone.0124676.t003){ref-type="table"}) \[[@pone.0124676.ref021]\]. These highly conserved amino acid residues are thought to allow *xl*EPO to cross-react with huEPOR and retain its proper orientation, avoiding interference from the added *N*-linked carbohydrates. With regard to *xl*EPOR, 7 of the 13 amino acid residues of huEPOR that interact with huEPO residues are conserved in *xl*EPOR (6 of 8 in site 1, 2 of 8 in site 2), which has an only 26% sequence identity with huEPOR in the extracellular domain ([Table 3](#pone.0124676.t003){ref-type="table"}) \[[@pone.0124676.ref049]\]. Further investigation is needed to understand why the added carbohydrates on *xl*EPO interfere with the *xl*EPOR binding but not with the huEPOR binding.

10.1371/journal.pone.0124676.t003

###### Amino acid residues of huEPO and huEPOR that contact each other in site 1 and site 2 intermolecular contact areas, and the corresponding residues in *xl*EPO.

![](pone.0124676.t003){#pone.0124676.t003g}

  Site 1     Site 2                                                                                                                                                                      
  ---------- ------------------- ------------------------------------------------------- ----------------------- ---------- ------------------- ---------------------------------------- -----------
  K9         *S9*                *H153*                                                                          P5         *L5*                ***F93***, **S204**                      F85, S195
  T10        [*R10*]{.ul}        *H153*, *E176*                                                                  **D8**     *D8*                *H153*                                   
  D13        E13                 P203                                                                            T10        [R10]{.ul}          M150, S152, H153                         
  I16        L16                 P203, **S204**                                          S195                    **V11**    ***V11***           ***F93***, M150, H153, **S204**          F85, S195
  K17        L17                 P203                                                                            M14        [***R14***]{.ul}    ***L33***, E34, P149, M150               L31
  R20        **K20**             E202, P203                                                                      F15        [***Y15***]{.ul}    S92, ***F93***                           F85
  **T44**    ***T44***           S92, ***F93***, V94                                     F85                     T78        Q78                 A88                                      
  **K45**    [***K45***]{.ul}    *E62*, S91, S92, **F93**, V94                           F85                     E91        [D96]{.ul}          T87, A88                                 
  L46        ***V46***           T90, S91, S92, ***F93***                                F85                     **K92**    [***K97***]{.ul}    *E34*                                    
  **N47**    N47                 T87, A88, **D89**, T90, S91                             D81                     H94        [V99]{.ul}          A88                                      
  V48        ***F48***           L33, E34, S92, ***F93***, F205                          F85                     **S95**    [***S100***]{.ul}   T87, A88, T90, *S91*                     
  G49        Y49                 E34, T87                                                                        **R98**    [***R103***]{.ul}   L59, *E62*, *A88*, **D89**, *S91*, V94   D81
  N52        [K52]{.ul}          E34                                                                             **S99**    [***S104***]{.ul}   S91, *S92*, ***F93***                    F85
  K121       R131                **E60**, **D61**, E62                                   E52, D53                H102       *T107*              ***F93***, V94                           F85
  L123       I133                **D61**                                                 D53                     **L103**   [***L108***]{.ul}   ***F93***                                F85
  **K130**   *K140*              ***E60***, ***D61***                                    E52, D53                K105       **R110**            **E60, D61**                             E52, D53
  S133       ***R143***          ***E60***, P95                                          E52                                                                                             
  **N137**   [***N147***]{.ul}   ***F93***, V94, P95, H114                               F85                                                                                             
  **R140**   [***R150***]{.ul}   ***F93***, H114, **N116**, ***E117***, P203, **S204**   F85, N107, E108, S195                                                                           
  **G141**   [***G151***]{.ul}   ***F93***                                               F85                                                                                             
  R144       K154                H153, **S204**                                          S195                                                                                            
  **L145**   ***L155***          ***F93***                                               F85                                                                                             

^*a*^ *xl*EPO residues corresponding to right-hand "huEPO residues" \[[@pone.0124676.ref021]\]. Amino acid residues that are identical to huEPO residues are in bold.

^*b*^Buried residues (\>5.0 Å^2^) of huEPO in site 1 and site 2 intermolecular contact areas \[[@pone.0124676.ref030]\]. Available mutagenesis information \[[@pone.0124676.ref026]--[@pone.0124676.ref029]\] are highlighted according to the maximal degree of loss of *in vitro* bioactivity: bold underlined, \>50-fold; bold, \>5-fold; underlined, 2--5-fold; not highlighted, no effect.

^*c*^HuEPOR residues within 4.5-Å distance from huEPO in the crystal structure of human EPO-(EPOR)~2~ complex (Protein Data Bank accession number, 1EER) \[[@pone.0124676.ref030]\]. Amino acid residues that are conserved in *X*. *laevis* are in bold \[[@pone.0124676.ref049]\].

^*d*^Amino acid residues of huEPO and huEPOR that form interactions with each other, such as hydrogen bond and hydrophobic binding, are in italics \[[@pone.0124676.ref030]\].

^*e*^Amino acid residues of *xl*EPOR that conserved in huEPOR\[[@pone.0124676.ref049]\].

huEPO, human erythropoietin; huEPOR, human EPO receptor; *xl*EPO, *X*. *laevis* EPO.

The most important finding presented here is that the carbohydrate structures, which are added to those *xl*EPO sites homologous to the *N*-glycosylation sites of huEPO, do not completely eliminate the *in vitro* biological activity of *xl*EPO, namely its binding to EPOR. This suggests that the functional region of *xl*EPO, which is responsible for its *in vitro* activity, must be located in a region other than the introduced *N*-glycosylation sites, as the 3 *N*-glycosylation sites of huEPO are distal to the receptor-binding site. We therefore conclude that a fundamental conformation of EPO-EPOR binding could be conserved between *X*. *laevis* and humans. Further point mutation study at the *xl*EPO-*xl*EPOR/huEPOR interface will give definite conclusions about their active sites. Furthemore, the key to understanding the observations presented here, as well as this conclusion, is the elucidation of the crystal structure of *xl*EPO in a complex with the extracellular domains of *xl*EPOR. Cross-species comparison of the tertiary structures of *X*. *laevis* and human EPOs (and other species such as fish) will facilitate the identification of the common denominators present in vertebrate EPOs.
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